Calliditas Therapeutics AB is a specialty pharmaceutical company based in Stockholm, Sweden. It is focused on developing high quality pharmaceutical products for patients with a significant unmet medical need in niche indications, in which Calliditas can partially or completely participate in the commercialization efforts. Calliditas is focused onthe development and commercialization of the product candidate Nefecon, a unique two step formulation optimized to combine a time lag effect with a concentrated release of the active substance budesonide, within a designated target area. This patented, locally acting formulation is intended for treatment of patients with the inflammatory renal disease IgA nephropathy (IgAN). Calliditas is running a global Phase 3 study within IgAN and aims to commercialize Nefecon in the United States.

Biotechnology

Pharmaceutical

Calliditas Therapeutics

Calliditas Therapeutics' headquarters in Stockholm, Sweden

Stefan Carlsson

Lars Jörgen Stubberud

Rowland Elwell

Michelle P.

Johan Häggblad

Teona Pipiya Johnson

Laura Roach

Karin Göhlin

Jeanette Roos

Fredrik Johansson

Emelie Bäckvall

Catherine Andrus

Description

People (13)

Marijn van der Sluijs

Fredrik Johansson

Emelie Johansson

Maria Andersson

Peter Einarsson

Jeanette Roos

Henrik S.

Anna Axelman

Johan Bexelius

Martin Allerbrand

Mark Biddle

Emelie Bäckvall

Oystein Lind

Jobs